Deutsche Bank Reconfirms “Buy” Rating for AstraZeneca PLC (LON:AZN) stock. What’s the Best Move for Investors?

July 27, 2018 - By Margaret Guttierez

AstraZeneca PLC (LON:AZN) Logo

AstraZeneca PLC (LON:AZN) Rating Reaffirmed

The rating of AstraZeneca PLC (LON:AZN) shares were restate by stock research analysts at Deutsche Bank. This was revealed to investors in a research note on 27 July.

AstraZeneca PLC (LON:AZN) Ratings Coverage

Among 15 analysts covering AstraZeneca PLC (LON:AZN), 11 have Buy rating, 0 Sell and 4 Hold. Therefore 73% are positive. AstraZeneca PLC has GBX 7800 highest and GBX 62 lowest target. GBX 5889.07’s average target is 2.35% above currents GBX 5754 stock price. AstraZeneca PLC had 70 analyst reports since January 30, 2018 according to SRatingsIntel. On Tuesday, June 5 the stock rating was maintained by Shore Capital with “Hold”. The stock has “Overweight” rating by Barclays Capital on Tuesday, July 10. On Friday, May 18 the stock rating was maintained by Berenberg with “Buy”. The stock has “Buy” rating by Jefferies on Monday, March 19. Deutsche Bank maintained AstraZeneca PLC (LON:AZN) on Friday, July 13 with “Buy” rating. As per Thursday, June 28, the company rating was maintained by Citigroup. The stock has “Buy” rating by Berenberg on Tuesday, May 29. As per Friday, June 15, the company rating was maintained by Jefferies. Shore Capital maintained AstraZeneca PLC (LON:AZN) on Friday, May 18 with “Hold” rating. Shore Capital maintained AstraZeneca PLC (LON:AZN) rating on Friday, May 25. Shore Capital has “Hold” rating and GBX 5428 target.

The stock decreased 0.72% or GBX 42 during the last trading session, reaching GBX 5754. About 641,843 shares traded. AstraZeneca PLC (LON:AZN) has 0.00% since July 27, 2017 and is . It has underperformed by 12.57% the S&P500.

AstraZeneca PLC develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of 72.88 billion GBP. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 25.99 P/E ratio. The company??s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.